Multi-gene cancer panels: what they are and who pays

A multigene test, often just called a panel, checks many genes at once for harmful changes. Instead of checking one suspect gene, it checks a whole list.

NCI explains that panels are often used when a family has no known gene mutation yet. That is the common case. Most people who consider testing do not have a relative with an identified gene change to test for. A panel casts a wider net.

Panels come in different sizes. A provider may order one that focuses on genes tied to one type of cancer, or a broad one that checks genes linked to several common cancers.

NCI's position on coverage is simple: health insurance typically covers genetic counseling and genetic tests seen as medically necessary.

The key phrase is "medically necessary." That is an insurance judgment. It depends on things like your own diagnosis, your family history, and what clinical guidelines say for people in your situation.

NCI's practical advice is to talk about costs and coverage with your health care provider and your insurance company before testing. Doing that first is the best way to avoid a surprise bill.

For people without coverage, NCI notes that uninsured people can get affordable genetic testing through groups that offer subsidized programs.

Ask about price and coverage before the sample is taken, not when the invoice arrives.

NCI reports that clinical guidelines recommend genetic testing for anyone diagnosed with triple-negative breast cancer, ovarian cancer, pancreatic cancer, colorectal cancer before age 50, metastatic prostate cancer, or male breast cancer.

If one of those applies to you, bring that fact into a coverage conversation. Testing that guidelines recommend stands on firmer ground when a plan decides what counts as necessary.

Casting a wider net catches more of everything, including findings nobody can yet explain.

NCI defines a variant of uncertain significance as a gene change with not enough data to know if it raises cancer risk or not. Such a variant may get reclassified later as researchers learn more.

That has a real effect. NCI says it matters for a person with an uncertain result to stay in touch with the provider who ran the test, so they hear about new findings on that variant.

An uncertain result is not a warning and not an all-clear either. It is an open file. Knowing that ahead of time softens the blow if you get one.

NCI is quite cautious about direct-to-consumer genetic testing. On the FDA-approved test for BRCA variants that you can buy yourself, it states that about 80% of cancer-causing BRCA variants are missed by this approach.

It also warns that both direct-to-consumer and consumer-driven genetic testing carry a higher risk of misreading the results.

A reassuring result from a test that only checks a small slice of possible changes is not the reassurance it looks like. If this question really matters to your health decisions, go through a clinician and a genetic counselor. That route gives you an answer you can actually trust.

Coverage disputes usually come down to details settled before the sample is even taken. It pays to be a little picky at that stage.

Ask which lab will run the test, and whether it is in network. Ask whether pre-authorization is being sought, and whether you will hear the answer before testing starts. Ask what the price would be if your plan says no, since labs often have a self-pay rate well below the list price.

Ask, too, whether the counseling visit and the test itself are billed separately. People sometimes budget for one and get surprised by the other.

None of this is unusual or rude to ask. Genetic services staff answer these questions every day, and someone on the team usually handles exactly this.

The bigger point: a panel test is a decision with medical, financial, and family effects all at once. Taking a little time to sort out the arrangements is a reasonable response to that, not overcaution.